Pliant Therapeutics Announces Upcoming Presentations
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a pioneer in developing innovative therapies for fibrotic diseases, has revealed plans for four important presentations at the European Respiratory Society (ERS) International Congress 2024. This congress will take place in Vienna and will highlight cutting-edge research in respiratory health and treatment alternatives.
Presentation Details
Late Breaker – Oral and ePoster Presentations
The first presentation will delve into the antifibrotic effects of bexotegrast, a dual ?V?6/?V?1 integrin inhibitor. Dr. Martin Decaris from Pliant Therapeutics will present this study, which evaluates the impact of bexotegrast using precision cut-lung slices obtained from non-IPF interstitial lung disease explants. This session is set for September 8 and will provide new insights into sarcoidosis.
Later Breaker – Oral and ePoster Presentations
Another intriguing presentation will examine the effects of bexotegrast on type 1 collagen deposition in patients with idiopathic pulmonary fibrosis (IPF) after 12 weeks of treatment. Dr. Sydney B. Montesi from Massachusetts General Hospital will share this vital research during a session focused on advancements in clinical practice for rare interstitial diseases.
Safety and Tolerability of Bexotegrast
Oral and Poster Presentations
Pliant Therapeutics will also present findings from Phase 2 trials assessing the safety and tolerability of bexotegrast in patients with IPF and primary sclerosing cholangitis (PSC). This presentation, led by Dr. Gregory Cosgrove from the company, is scheduled for September 9 and will discuss innovative management strategies that could transform treatment for pulmonary fibrosis.
Poster Presentation on Biomarkers
Additionally, a poster presentation will focus on a post-hoc biomarker analysis involving IPF participants who received bexotegrast over a 12-week period. Dr. Martin Decaris will share insights from this analysis during a session on the pathogenesis of pulmonary fibrosis and serum biomarkers on September 10.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is committed to discovering and developing treatments for fibrotic diseases. Its leading product candidate, bexotegrast (PLN-74809), aims to offer groundbreaking solutions for conditions like IPF and PSC. The company has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA for these conditions. Furthermore, Pliant has launched the BEACON-IPF trial, a crucial Phase 2b/3 study investigating the efficacy of bexotegrast.
In addition to these advancements, Pliant is also advancing PLN-101095, a new small molecule targeting solid tumors, and has obtained regulatory approval for a Phase 1 study of PLN-101325, which focuses on muscular dystrophies.
Contact Information
For further details, please visit Pliant Therapeutics' website. For inquiries from investors and the media, please reach out to Christopher Keenan, Vice President of Investor Relations and Corporate Communications at Pliant Therapeutics, Inc. via email at ir@pliantrx.com.
Frequently Asked Questions
What is the focus of the upcoming presentations by Pliant Therapeutics?
The presentations will concentrate on innovative research regarding the antifibrotic activity of bexotegrast, a treatment for fibrotic diseases.
When will the European Respiratory Society International Congress take place?
The congress is scheduled to occur from September 7 to September 11, 2024.
Where can I find more information about Pliant Therapeutics?
You can find additional information on Pliant Therapeutics' official website.
What is bexotegrast?
Bexotegrast is Pliant's primary product candidate, designed as a dual selective inhibitor targeting integrins associated with fibrotic diseases.
Who should contact Pliant Therapeutics for investor inquiries?
Investor inquiries should be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications.
